title: Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model.
abstract: Although AIMP1 (previously known as p43) is one of three auxiliary proteins bound to a macromolecular aminoacyl tRNA complex, it is also secreted as a cytokine controlling both angiogenesis and immune responses. Here we show that systemically administered purified recombinant human AIMP1 had anti-tumor activity in mouse xenograft models. In Meth A-bearing Balb/c mice, tumor volume increased about 28 fold in the vehicle treatment group, while an increase of about 16.7 fold was observed in the AIMP1-treated group. We also evaluated the anti-tumor activity of AIMP1 in combination with a sub-clinical dose of the cytotoxic anti-tumor drug, paclitaxel. The growth of NUGC-3 human stomach cancer cells was suppressed by 84% and 94% by the combinations of 5 mg/kg paclitaxel + 25 mg/kg AIMP1 (p = 0.03), and 5 mg/kg paclitaxel + 50 mg/kg AIMP1 (p = 0.02), respectively, while 5 mg/kg paclitaxel alone suppressed growth by only 54% (p = 0.02). A similar cooperative effect of AIMP1 and paclitaxel was observed in a lung cancer xenograft model. These results suggest that AIMP1 may be useful as a novel anti-tumor agent.
authors: National Creative Research Initiatives Center for ARS Network, College of Pharmacy Seoul National University, Seoul 151-742, Korea.
authors: Yeon-Sook
authors: YS
authors: Lee
authors: Jung Min
authors: JM
authors: Han
authors: Taehee
authors: T
authors: Kang
authors: Young In
authors: YI
authors: Park
authors: Hwan Mook
authors: HM
authors: Kim
authors: Sunghoon
authors: S
authors: Kim